The Rechallenge of ADCs in MBC Patients

N/AActive Not RecruitingNCT05571618

Fudan University100 enrolled

Overview

To investigate the efficacy and safety of ADC rechallenge

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Breast Cancer

Interventions

ADCDRUG

Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \> 18 years old. * Diagnosed with Metastatic Breast Cancer. * Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed). * Patients plan to or have received ADCs for the second or more time. * Complete medical history was available. Exclusion Criteria: * Medical history was incomplete

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Secondary Outcomes

ORR

Objective Response Rate

Time frame: 6 weeks

CBR

Clinical Benefit Rate

Time frame: 6 weeks

DoR

Duration of Response

Time frame: 6 weeks

Adverse events

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Time frame: 6 weeks

Overall Survival

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.